SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-006554
Filing Date
2024-01-25
Accepted
2024-01-25 17:24:53
Documents
13
Period of Report
2024-01-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192203-8k_allarity.htm   iXBRL 8-K 27877
2 AMENDMENT TO SECURITIES PURCHASE AGREEMENT, DATED AS OF JANUARY 25, 2024, BY AND ea192203ex10-1_allarity.htm EX-10.1 16899
  Complete submission text file 0001213900-24-006554.txt   223592

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE allr-20240125.xsd EX-101.SCH 3015
4 XBRL LABEL FILE allr-20240125_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE allr-20240125_pre.xml EX-101.PRE 22359
7 EXTRACTED XBRL INSTANCE DOCUMENT ea192203-8k_allarity_htm.xml XML 3414
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24563297
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)